Cell Structures in Heterologous Anti-Rabies Immunoglobulin Production
https://doi.org/10.21055/0370-1069-2011-4(110)-76-79
Abstract
This paper reviews basic modern trends in obtainment of anti-rabies immunoglobulin with enhanced properties. One of these trends is associated with the substitution of organ-tissue antigen by cultural antigen at the stage of producer immunization. Analyzed are the results of research connected with the use of the cell-cultures grown Rabies virus in production of heterologous anti-rabies immunoglobulin. The study testifies of applicability of the transferred Vero cell culture as a substrate for rabies antigen preparation. In addition to this, specified are the advantages of the rabies cultural antigen usage over the organ-tissue one at the stage of hyper-immune serum production.
Keywords
616.988.21
About the Authors
S. V. Generalov
Russian Research Anti-Plague Institute Microbe
Russian Federation
Russian Federation
E. G. Abramova
Russian Research Anti-Plague Institute Microbe
Russian Federation
Russian Federation
A. K. Nikiforov
Russian Research Anti-Plague Institute Microbe
Russian Federation
Russian Federation
Zh. V. Matveeva
Russian Research Anti-Plague Institute Microbe
Russian Federation
Russian Federation
References
1. Abramova E.G., Nikiforov A.K., Lobovikova O.A., Eremin S.A., Vasin Yu.G., Mikheeva T.A. et al. [Heterologous anti-rabies immunoglobulin – re- sults of the first five years of production]. Probl. Osobo Opasn. Infek. 2010; 105:58–62.
2. Babkin M.V., Stegny B.T., Nichik S.A., Prokhoryatova E.V., Kucheryavenko R.A., Godovsky A.V. [Method of obtainment of hyper-immune anti-rabies serum]. UA Patent 19403.
3. Generalov S.V., Abramova E.G., Nikiforov A.K., Khramkova E.M., Shepelev I.A., Savitskaya L.V. et al. [F(ab’)2-fragments of anti-rabies imuno- globulin production using immobilized pepsin]. Probl. Osobo Opasn. Infek. 2008; 97:53–6.
4. Kaplan M.M., Koprovsky Kh., editors. [Methods for Laboratory Investigations of Rabies Virus]. Geneva: WHO; 1975. 360 p.
5. Karpov S.P., Preger S.M., Sinel’nikov G.E., Fedorov Yu.V. [Hyper- Immune Sera]. Tomsk; 1976. 380 p.
6. Nagieva F.G., Bektemirova M.S., Matevosyan K.Sh., Bektemirov T.A., Pile E.R. [Reproduction of the fixed rabies virus in the culture of quail fibroblasts that grow in suspension]. Vopr. Virusol. 1980; 4:429–31.
7. Nedosekov V.V., Slivko I.A., Kurinnov V.V., Lunitsin A.V., Gruzdev K.N. [Method of obtainment of hyper-immune antirabic serum]. RF patent 2196607.
8. Selimov M.A.[Rabies Virus]. M.: Meditsina; 1978. 336 p.
9. Sitnik N.P., Zagidullin N.V., Israfilov A.G., Enikeeva L.F., Mukhacheva A.V., Shafeeva R.S. et al. [Method of obtainment of highly specific heterolo- gous anti-rabies serum]. RF patent 2322503.
10. Sitnik N.P., Israfilov A.G., Zagidullin N.V., Alsynbaev M.M., Timerbaeva R.Kh. [Preparation of heterologous anti-rabies immunoglobulin for intravenous and intramuscular injections, and method of its obtainment]. RF patent 2339401.
11. Tikhonov I.V., Ruban E.A., Gryazneva T.N. [Biotechnology]. St. Petersburg.: GIORD; 2005. 792 p.
12. Shafeeva R.S., Frolova A.V., Mullagulova M.N. [Production of concentrated purified cultural anti-rabies vaccine within the frames of experi- ment on the basis of transferred Vero cells]. In: [Role of Immunobiological Preparations in Modern Medicine].Ufa; 1995. Vol. 1. P. 191–4.
13. Barrett P., Mundt W., Kistner O., Howard M. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert. Rev. Vaccines. 2009; 8:607-18.
14. Brookes S., Parsons G., Johnson N., McElhinney L., Fooks A. Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine. 2005; 23:4101-9.
15. Consales C.A., Valentini E.J.G., Albas A., Mendonca R., Fuches R., Soares M.A. et. al. The preparation of cultured rabies virus and the production of antiserum fffor human use. Journal of Biological Standartization. 1988; 16:27-32.
16. Costa W., Cunha R., Bolzan V., Silva Ade C., Caporale G., Chaves L. et al. Immunogenicity and safety of a new Vero cell rabies vaccine produced using serum-free medium. Vaccine. 2007; 25:8140-5.
17. Goel S.K., Sharma S., Singh U. Antibody response to purified chick embryo cell vaccine in equines for production of equine rabies immune globulin. Biologicals. 2003; 31:233-6.
18. Hong H., Rooijakkers E., Ke N., Groen J., Osterhaus A. Methods for the purification of equine rabies immunoglobulin: effects on yield and biological activity. Biological. 1994; 22:1-6.
19. Kallel H., Rourou S., Majoul S., Loukil H. A novel process for the purification of veterinary rabies vaccine in BHK-21 cells grown on microcarriers in 20-l bioreactor. Appl. Microbiol. Biotechnol. 2003; 61:441-6.
20. Karliner J.S., Belaval G.S. Incidence of reactions following administration of antirabies serum: a study of 526 cases. JAMA. 1965; 193:359-62.
21. Kumar A., Mani K., Palaniappan C., Bhau L., Swaminathan K. Purification, potency and immunogenicity analysis of Vero cell culture-derived rabies vaccine: a comparative study of single-step column chromatography and zonal centrifuge purification. Microbes Infect. 2005; 7:1110-6.
22. Lalosević D., Lalosević V., Lazarević-Ivanc Lj., Knezević I. BHK-21 cell culture rabies vaccine: immunogenicity of a candidate vaccine for humans. Dev. Biol. (Basel). 2008; 131:421-9.
23. Lang J., Attanath P., Quiambao B., Singhasivanon V., Chanthavanich P., Montalban C. et. al. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. Acta Tropica. 1998; 70:317-33.
24. Luekrajan T., Wangsai J., Phanuphak P. Production of antirabies serum of equine origin. In: Meslin F.-X., Kaplan M.M., Koprowsky H, editors. Laboratory techniques in rabies. Geneva: WHO; 1996. P. 401-4.
25. Madhusudana S., Anand N., Shamsundar R. Economical multi-site intradermal regimen with purified chick embryo cell vaccine (Rabipur) prevents rabies in people bitten by confirmed rabid animals. Int. J. Infect. Dis. 2002; 6:210-4.
26. Motoi Y., Sato K., Hatta H., Morimoto K., Inoue S., Yamada A. Production of rabies neutralizing antibody in hen's eggs using a part of the G protein expressed in Escherichia coli. Vaccine. 2005; 23:3026-32.
27. Müller T., Dietzschold B., Ertl H., Fooks A.R., Freuling C., Fehlner-Gardiner C. et. al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS. Negl. Trop. Dis. 2009; 3(11):e542.
28. Nagarajan T., Rupprecht C.E., Dessain S.K., Rangarajan P.N., Thiagarajan D., Srinivasan V.A. Human monoclonal antibody and vaccine approaches to prevent human rabies. Curr. Top. Microbiol. Immunol. 2008; 317:67-101.
29. Ozkan O., Aylan O., Ates C., Celebi B. Production of heterolog anti-rabies immune sera. Etlik Veteriner Mikrobiyoloji Dergisi. 2004; 15:49-54.
30. Perez O., Paolazzi C. Production methods for rabies vaccine. Journal of industrial microbiology & biotechnology. 1997; 18:340-7.
31. Redwan el-R.M., Fahmy A., El Hanafy A., Abd El-Baky N., Sallam S.M. Ovine anti-rabies antibody production and evaluation. Comp. Immunol. Microbiol. Infect. Dis. 2009; 32:9-19.
32. Rourou S., van der Ark A., van der Velden T., Kallel H.A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions. Vaccine. 2007; 25:3879-89.
33. Satoru Y., Akira N., Tadasuke A. Human Fab antibody gene cluster for effectively neutralizing rabies virus. Patent JP № 2006166905, IPC C12N15/09, 29.06.2006.
34. Wilde H., Chomchey P., Prakongsri S., Puyaratabanhu, Chutivongse S. Adverse effects of equine rabies immune globulin. Vaccine. 1989; 7:10-11.
35. Wilde H., Khawplod P., Hemachudha T., Sitprija V. Postexposure treatment of rabies infection: can it be done without immunoglobulin? Clin. Infect. Dis. 2002; 34:477-80.
36. WHO Expert Consultation on Rabies: first report. WHO technical report series 931. Geneva; 2004. 121 p.
37. Yunde H., Shizen Zh., Mifang L. Humanized genetically engineered neutralizing antibody of rabies virus. Patent CN № 1355253. IPC C07K16/08. 26.06.2002.
Review
For citations:
Generalov S.V., Abramova E.G., Nikiforov A.K., Matveeva Zh.V. Cell Structures in Heterologous Anti-Rabies Immunoglobulin Production. Problems of Particularly Dangerous Infections. 2011;(4(110)):76-79. (In Russ.) https://doi.org/10.21055/0370-1069-2011-4(110)-76-79
Views:
592
Email this article 